Research ExplorerPublicationsSexual dimorphism in solid and hematological malignancies

Sexual dimorphism in solid and hematological malignancies

Standard

Sexual dimorphism in solid and hematological malignancies. / Ben-Batalla, Isabel; Vargas-Delgado, María Elena; Meier, Lara; Loges, Sonja.

In: SEMIN IMMUNOPATHOL, Vol. 41, No. 2, 01.03.2019, p. 251-263.

Research output: SCORING: Contribution to journal › SCORING: Review article › Research

Harvard

Ben-Batalla, I, Vargas-Delgado, ME, Meier, L & Loges, S 2019, 'Sexual dimorphism in solid and hematological malignancies', SEMIN IMMUNOPATHOL, vol. 41, no. 2, pp. 251-263. https://doi.org/10.1007/s00281-018-0724-7

APA

Ben-Batalla, I., Vargas-Delgado, M. E., Meier, L., & Loges, S. (2019). Sexual dimorphism in solid and hematological malignancies. SEMIN IMMUNOPATHOL, 41(2), 251-263. https://doi.org/10.1007/s00281-018-0724-7

Vancouver

Ben-Batalla I, Vargas-Delgado ME, Meier L, Loges S. Sexual dimorphism in solid and hematological malignancies. SEMIN IMMUNOPATHOL. 2019 Mar 1;41(2):251-263. https://doi.org/10.1007/s00281-018-0724-7

Bibtex

@article{fa61319d81db442a867733b5bf1863e3,
title = "Sexual dimorphism in solid and hematological malignancies",
abstract = "Cancer represents a leading cause of death with continuously increasing incidence worldwide. Many solid cancer types in non-reproductive organs are significantly more frequent and deadly in males compared to females. This sex-biased difference is also present in hematologic malignancies. In this review, we present an overview about sex differences in cancer with a focus on leukemia. We discuss mechanisms potentially underlying the observed sex-biased imbalance in cancer incidence and outcome including sex hormones, sex chromosomes, and immune responses. Besides affecting the pathobiology of cancers, sex differences can also influence drug responses, most notably those to immune checkpoint blockers. Therefore, sex should become a relevant factor in clinical trial design in order to avoid over- or under-treatment of one sex.",
keywords = "Journal Article, Review",
author = "Isabel Ben-Batalla and Vargas-Delgado, {Mar{\'i}a Elena} and Lara Meier and Sonja Loges",
year = "2019",
month = mar,
day = "1",
doi = "10.1007/s00281-018-0724-7",
language = "English",
volume = "41",
pages = "251--263",
journal = "SEMIN IMMUNOPATHOL",
issn = "1863-2297",
publisher = "Springer",
number = "2",

}

RIS

TY - JOUR

T1 - Sexual dimorphism in solid and hematological malignancies

AU - Ben-Batalla, Isabel

AU - Vargas-Delgado, María Elena

AU - Meier, Lara

AU - Loges, Sonja

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Cancer represents a leading cause of death with continuously increasing incidence worldwide. Many solid cancer types in non-reproductive organs are significantly more frequent and deadly in males compared to females. This sex-biased difference is also present in hematologic malignancies. In this review, we present an overview about sex differences in cancer with a focus on leukemia. We discuss mechanisms potentially underlying the observed sex-biased imbalance in cancer incidence and outcome including sex hormones, sex chromosomes, and immune responses. Besides affecting the pathobiology of cancers, sex differences can also influence drug responses, most notably those to immune checkpoint blockers. Therefore, sex should become a relevant factor in clinical trial design in order to avoid over- or under-treatment of one sex.

AB - Cancer represents a leading cause of death with continuously increasing incidence worldwide. Many solid cancer types in non-reproductive organs are significantly more frequent and deadly in males compared to females. This sex-biased difference is also present in hematologic malignancies. In this review, we present an overview about sex differences in cancer with a focus on leukemia. We discuss mechanisms potentially underlying the observed sex-biased imbalance in cancer incidence and outcome including sex hormones, sex chromosomes, and immune responses. Besides affecting the pathobiology of cancers, sex differences can also influence drug responses, most notably those to immune checkpoint blockers. Therefore, sex should become a relevant factor in clinical trial design in order to avoid over- or under-treatment of one sex.

KW - Journal Article

KW - Review

U2 - 10.1007/s00281-018-0724-7

DO - 10.1007/s00281-018-0724-7

M3 - SCORING: Review article

C2 - 30361802

VL - 41

SP - 251

EP - 263

JO - SEMIN IMMUNOPATHOL

JF - SEMIN IMMUNOPATHOL

SN - 1863-2297

IS - 2

ER -